182 related articles for article (PubMed ID: 28858970)
41. Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres.
Boussaud V; Guillemain R; Grenet D; Coley N; Souilamas R; Bonnette P; Stern M
Thorax; 2008 Aug; 63(8):732-7. PubMed ID: 18408050
[TBL] [Abstract][Full Text] [Related]
42. Chronic infection with Pseudomonas aeruginosa in cystic fibrosis: a risk factor for nasal polyposis after lung transplantation.
Vital D; Holzmann D; Boehler A; Hofer M
Transplantation; 2013 Jun; 95(12):1548-53. PubMed ID: 23624545
[TBL] [Abstract][Full Text] [Related]
43. Transplant center volume and outcomes in lung transplantation for cystic fibrosis.
Hayes D; Sweet SC; Benden C; Kopp BT; Goldfarb SB; Visner GA; Mallory GB; Tobias JD; Tumin D
Transpl Int; 2017 Apr; 30(4):371-377. PubMed ID: 28012223
[TBL] [Abstract][Full Text] [Related]
44. Lung infections in pediatric lung transplantation: experience in 49 cases.
Metras D; Viard L; Kreitmann B; Riberi A; Pannetier-Mille A; Garbi O; Marti JY; Geigle P
Eur J Cardiothorac Surg; 1999 Apr; 15(4):490-4; discussion 495. PubMed ID: 10371127
[TBL] [Abstract][Full Text] [Related]
45. Lung transplantation for cystic fibrosis: an update.
Chaparro C; Keshavjee S
Expert Rev Respir Med; 2016 Dec; 10(12):1269-1280. PubMed ID: 27842444
[TBL] [Abstract][Full Text] [Related]
46. Current dilemmas in antimicrobial therapy in cystic fibrosis.
Jain K; Smyth AR
Expert Rev Respir Med; 2012 Aug; 6(4):407-22. PubMed ID: 22971066
[TBL] [Abstract][Full Text] [Related]
47. Pretransplant HRCT Characteristics Are Associated with Worse Outcome of Lung Transplantation for Cystic Fibrosis Patients.
Belle-van Meerkerk G; de Jong PA; de Valk HW; Neefjes T; Pameijer FA; Kwakkel-van Erp JM; van de Graaf EA
PLoS One; 2015; 10(12):e0145597. PubMed ID: 26698308
[TBL] [Abstract][Full Text] [Related]
48. New treatments for emerging cystic fibrosis pathogens other than Pseudomonas.
Waters V
Curr Pharm Des; 2012; 18(5):696-725. PubMed ID: 22229574
[TBL] [Abstract][Full Text] [Related]
49. [Protocol for the diagnosis and follow up of patients with cystic fibrosis].
Barrio Gómez de Agüero MI; García Hernández G; Gartner S;
An Pediatr (Barc); 2009 Sep; 71(3):250-64. PubMed ID: 19643690
[TBL] [Abstract][Full Text] [Related]
50. Lung transplantation in patients with cystic fibrosis and Mycobacterium abscessus infection.
Gilljam M; Scherstén H; Silverborn M; Jönsson B; Ericsson Hollsing A
J Cyst Fibros; 2010 Jul; 9(4):272-6. PubMed ID: 20400381
[TBL] [Abstract][Full Text] [Related]
51. Comparing Mycobacterium massiliense and Mycobacterium abscessus lung infections in cystic fibrosis patients.
Roux AL; Catherinot E; Soismier N; Heym B; Bellis G; Lemonnier L; Chiron R; Fauroux B; Le Bourgeois M; Munck A; Pin I; Sermet I; Gutierrez C; Véziris N; Jarlier V; Cambau E; Herrmann JL; Guillemot D; Gaillard JL;
J Cyst Fibros; 2015 Jan; 14(1):63-9. PubMed ID: 25085077
[TBL] [Abstract][Full Text] [Related]
52. Airway dehiscence after lung transplantation in a patient with cystic fibrosis.
Hayes D; Hatton KW; Feola DJ; Murphy BS; Mullett TW
Respir Care; 2010 Dec; 55(12):1746-50. PubMed ID: 21122182
[TBL] [Abstract][Full Text] [Related]
53. Epidemic Pseudomonas aeruginosa infection in patients with cystic fibrosis is not a risk factor for poor clinical Outcomes following lung transplantation.
Pritchard J; Thakrar MV; Somayaji R; Surette MG; Rabin HR; Helmersen D; Lien D; Purighalla S; Waddell B; Parkins MD
J Cyst Fibros; 2016 May; 15(3):392-9. PubMed ID: 26657575
[TBL] [Abstract][Full Text] [Related]
54. Special considerations for patients with cystic fibrosis undergoing lung transplantation.
Hadjiliadis D
Chest; 2007 Apr; 131(4):1224-31. PubMed ID: 17426231
[TBL] [Abstract][Full Text] [Related]
55. Cystic fibrosis lung environment and Pseudomonas aeruginosa infection.
Bhagirath AY; Li Y; Somayajula D; Dadashi M; Badr S; Duan K
BMC Pulm Med; 2016 Dec; 16(1):174. PubMed ID: 27919253
[TBL] [Abstract][Full Text] [Related]
56. Lung transplantation in patients with cystic fibrosis: special focus to infection and comorbidities.
Dorgan DJ; Hadjiliadis D
Expert Rev Respir Med; 2014 Jun; 8(3):315-26. PubMed ID: 24655065
[TBL] [Abstract][Full Text] [Related]
57. Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection.
Govan JR; Brown AR; Jones AM
Future Microbiol; 2007 Apr; 2(2):153-64. PubMed ID: 17661652
[TBL] [Abstract][Full Text] [Related]
58. Impact of gram negative bacteria airway recolonization on the occurrence of chronic lung allograft dysfunction after lung transplantation in a population of cystic fibrosis patients.
Orfanos S; Gomez C; Baron S; Akkisetty R; Dufeu N; Coltey B; Thomas PA; Rolain JM; Reynaud-Gaubert M
BMC Microbiol; 2018 Aug; 18(1):88. PubMed ID: 30126365
[TBL] [Abstract][Full Text] [Related]
59. Mycobacterium abscessus and other nontuberculous mycobacteria: evolving respiratory pathogens in cystic fibrosis: a case report and review.
Hayes D
South Med J; 2005 Jun; 98(6):657-61. PubMed ID: 16004174
[TBL] [Abstract][Full Text] [Related]
60. Use of taurolidine in lung transplantation for cystic fibrosis and impact on bacterial colonization.
Zeriouh M; Sabashnikov A; Patil NP; Schmack B; Zych B; Mohite PN; García Sáez D; Koch A; Mansur A; Soresi S; Weymann A; Marczin N; Wahlers T; De Robertis F; Simon AR; Popov AF
Eur J Cardiothorac Surg; 2018 Mar; 53(3):603-609. PubMed ID: 29048473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
